CompanyNAMS NAMSWNasdaqNarrden, P7

NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease risk.

SEC EDGAR ClinicalTrials.gov ir.newamsterdampharma.com

8-KSep 29Latest SEC filing

Sep 28Latest story

September 2026

AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adults

Sep 28Weekly roundup, 2 itemsacalabrutinib AstraZeneca

August 2026

NewAmsterdam Pharma names new accounting officer, details COO exit terms

Aug 14PeopleNewAmsterdam Pharma Co N.V.

NewAmsterdam reports positive CHMP opinion for obicetrapib, sets PREVAIL and RUBENS timelines

Aug 5Quarterly updateNewAmsterdam Pharma Co N.V.

July 2026

NewAmsterdam and Menarini get positive EU CHMP opinion for obicetrapib medicines

Jul 24Regulatory milestoneNewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma's COO Kling to resign, take CEO role elsewhere

Jul 22PeopleNewAmsterdam Pharma Co N.V.